GlassScriptPhysician profile
Gerald W Engstrom
NPI 1609851898
$1,107.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $86.05 · 2021: $241 · 2022: $210 · 2023: $133 · 2024: $30.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198.46 | 2019-2024 | |
| Gilead Sciences, INC. | $184.85 | 2019-2020 | |
| Janssen Biotech, INC. | $161.96 | 2021-2023 | Stelara |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Pfizer INC. | $117.42 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.95 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $50.67 | 2020 | |
| Nestle Healthcare Nutrition INC. | $45.68 | 2021-2023 | |
| Genzyme Corporation | $36.15 | 2022-2023 | |
| Braintree Laboratories, INC. | $30.98 | 2019-2023 | Suflave |
| Celgene Corporation | $30.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.73 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.12 | 2022 | |
| Daiichi Sankyo INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Engstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.